Cayman Chemical Q-Plex Autoantibody Detection 10-Plex Panel

Cayman Chemical’s Q-Plex Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardised multiplex capabilities for the concurrent analysis of 10 prominent analytes associated with rheumatoid arthritis or other autoimmune diseases.

The qualitative, chemiluminescent ELISA measures human antibodies against PAD3, PAD4, fibrinogen, citrullinated fibrinogen, carbamylated fibrinogen, human core histones, citrullinated histones, carbamylated histones, α-enolase and citrullinated α-enolase in plasma and serum samples, enabling the mapping of a complex biomarker signature to certain inflammatory diseases. Compared to running multiple single assays, the multiplex assay platform is said to be more robust and informative than single analyte detection, providing greater experimental control, more efficient use of labour efforts and a more economical approach.

The assay plates are built by adsorbing each distinct antibody or protein in a defined array to the bottom of each well. Samples or controls are pipetted into these wells along with high-quality reagents provided in each kit to enable the detection of the analytes and to help ensure the accuracy of the results. Q-Plex multiplexing technology detects antibodies and antigens in samples even at low concentrations, providing high specificity and sensitivity using a traditional ELISA protocol. Leveraging an expanded dynamic range, the product should decrease the need for multiple dilutions and measures high- and low-abundance analytes in the same assay.